About BioLife Solutions:

The Company’s proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife’s biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death.  BioLife’s enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs.  BioLife also performs contract aseptic media formulation, fill, and finish services. 

  • Price Data
  • Events
  • Markets
  • SEC Filings
  • Presentations
Thursday, August 11, 2016
1:30pm - 2:30pm PDT
Tuesday, March 22, 2016

Today BioLife Solutions announced that CEO Mike Rice will be presenting at the 4th Annual Alliance for Regenerative Medicine Cell & Gene Therapy Investor Day on Tuesday, March 22, 2016 at the...

Sunday, March 13, 2016 - Wednesday, March 16, 2016

Today BioLife Solutions announced that CEO Mike Rice will be presenting at the 28th Annual ROTH Conference; March 13-16, 2016 at the Ritz Carlton in Dana Point, CA. The presentation time will be...

More Events >

About BioLife Solutions Addressable Markets

  • In July 2015, Frost & Sullivan forecasted that the stem cell therapy market is expected to be worth $40 billion by 2020 and $180 billion by 2030.
  • Pharmaceutical Commerce estimates that in 2015, $10 billion was spent on cold chain logistics of pharmaceuticals, with $7 billion for transportation and $3 billion for specialized packaging and instrumentation. BioLife's addressable market is comprised of the demand for small payload shipping containers and related temperature monitoring and location tracking devices.
  • Global Industry Analysts, Inc. estimates in their September 2015 Organ Preservation Solutions, A Global Strategic Business Report that the worldwide demand for organ cold storage solutions was $85.5 million in 2014, and is expected to grow 109% to over $175 million in 2020.

Read about our markets:

Regenerative Medicine
Drug Discovery

Loading data...

BioLife Investor Presentation September 2016

Print Friendly